Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK

Publication date: Available online 26 March 2020Source: Diabetes & Metabolic Syndrome: Clinical Research & ReviewsAuthor(s): Natasha Shrikrishnapalasuriyar, Ayesha Shaikh, Aliya Mohd Ruslan, Giselle Asharaf, Maneesh Udiawar, David E. Price, Jeffrey W. Stephens
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research